Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1

Interventions

Specimen Handling 219pembrolizumab 198Magnetic Resonance Spectroscopy 197Carboplatin 174Cisplatin 140Biopsy 133Nivolumab 131Paclitaxel 115Radiotherapy 111Cyclophosphamide 111Gemcitabine 104durvalumab 90Dexamethasone 90atezolizumab 77Radiation 72Rituximab 71Lenalidomide 69Pemetrexed 66Bevacizumab 66Doxorubicin 65Docetaxel 63Ipilimumab 59Etoposide 57olaparib 54Fluorouracil 52venetoclax 50Taxes 50Oxaliplatin 50Radiosurgery 49Prednisone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × 3-fluorobenzylguanidine × 90 days × Clear all
NCT04724369 2026-04-03

Open-Label Study of 18F-mFBG for Imaging Neuroblastoma

Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)

Phase 3 Active not recruiting
43 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡